Social Functioning in Opioid Use Disorder

ConditionOpioid Use Disorder

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorMedical University of South Carolina

About this trial

Problems with social functioning are core to opioid use disorder (OUD), though specific, modifiable social functioning targets and how they relate to OUD treatment outcomes are poorly understood. This study will utilize both data from both patients with OUD and their concerned significant other (CSO) to examine associations between specific social functioning metrics and OUD treatment outcomes. Findings from this study will inform future precision-medicine approaches for people with OUD, a population in significant need of enhanced treatment approaches to combat opioid morbidity and mortality.

Eligibility criteria

Qualifiers

Any sex or gender; any race or ethnicity; aged 18 years or older

Patient participants must meet DSM-5 diagnostic criteria for current (i.e., past 12 months) OUD (assessed via the Quick Structured Clinical Interview for DSM-5; Quick SCID)

Patient participants must be on medication for opioid use disorder (MOUD), as prescribed by their provider, for no more than 12 weeks prior to study initiation

Patient participants must be in treatment at a clinic in South Carolina

Disqualifiers

Moderate-to-severe opioid withdrawal as defined by a score of ≥21 on the Subjective Opioid Withdrawal Scale

Meeting DSM-5 criteria for a history of or current psychotic or bipolar disorders

Current suicidal or homicidal ideation and intent; participants who present a serious suicide risk are likely to require hospitalization during the study and they will be referred clinically

CSO participants meeting DSM-5 criteria for opioid use disorder or any other substance use disorder, excepting tobacco use disorder, mild cannabis use disorder, and mild alcohol use disorder

Trial design

Treatments tested in this trial

CBT4CBT-Buprenorphine

Treatment groups

230 Participants

are divided into 1 treatment group

Sponsors and collaborators

Medical University of South Carolina

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator

National Institutes of Health (NIH)

Collaborator

Source ClinicalTrials.gov